Sepiapterin inhibits cell proliferation and migration of ovarian cancer cells via down-regulation of p70 S6K-dependent VEGFR-2 expression

Oncology Reports

Volumn 26, Issue 4, 2011, Pages 861-867

  Cho, Young Rak ^a   Kim, Soo Hyeon ^a   Ko, Hee Young ^a   Kim, Myoung Dong ^a   Choi, Shin Wook ^b   Seo, Dong Wan ^a  

^a Kangwon National University   (South Korea)

^b Radiant Research Institute   (South Korea)

Author keywords

Nitric oxide; Ovarian cancer; Sepiapterin; Tetrahydrobiopterin; Vascular endothelial growth factor A

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; PROTEIN KINASE B; S6 KINASE; SEPIAPTERIN; VASCULOTROPIN RECEPTOR 2;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL FATE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; MIGRATION INHIBITION; MITOSIS INHIBITION; MOLECULAR DYNAMICS; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; DOWN-REGULATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; NITRIC OXIDE; ONCOGENE PROTEIN V-AKT; OVARIAN NEOPLASMS; PTERINS; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 79960810239     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1335     Document Type: Article

References (35)

1. Thony B, Auerbach G and Blau N: Tetrahydrobiopterin biosynthesis, regeneration and functions. Biochem J 347: 1-16, 2000. (Pubitemid 30199034)
2. Gao L, Pung YF, Zhang J, et al: Sepiapterin reductase regulation of endothelial tetrahydrobiopterin and nitric oxide bioavailability. Am J Physiol Heart Circ Physiol 297: H331-H339, 2009.
3. Sumi-Ichinose C, Urano F, Kuroda R, et al: Catecholamines and serotonin are differently regulated by tetrahydrobiopterin. J Biol Chem 276: 41150-41160, 2001.
4. Anastasiadis PZ, States JC, Imerman BA, Louie MC, Kuhn DM and Levine RA: Mitogenic effects of tetrahydrobiopterin in PC12 cells. Mol Pharmacol 49: 149-155, 1996. (Pubitemid 26036791)
5. Ziche M, Morbidelli L, Masini E, et al: Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Invest 94: 2036-2044, 1994. (Pubitemid 24348244)
6. Ziche M, Morbidelli L, Choudhuri R, et al: Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 99: 2625-2634, 1997. (Pubitemid 27259809)
7. Chen L, Zeng X, Wang J, et al: Roles of tetrahydrobiopterin in promoting tumor angiogenesis. Am J Pathol 177: 2671-2680, 2010.
8. Pannirselvam M, Wiehler WB, Anderson T and Triggle CR: Enhanced vascular reactivity of small mesenteric arteries from diabetic mice is associated with enhanced oxidative stress and cyclooxygenase products. Br J Pharmacol 144: 953-960, 2005. (Pubitemid 40593021)
9. Shang T, Kotamraju S, Zhao H, Kalivendi SV, Hillard CJ and Kalyanaraman B: Sepiapterin attenuates 1-methyl-4-phenylpyridinium-induced apoptosis in neuroblastoma cells transfected with neuronal NOS: role of tetrahydrobiopterin, nitric oxide, and proteasome activation. Free Radic Biol Med 39: 1059-1074, 2005. (Pubitemid 41356597)
10. Spannuth WA, Sood AK and Coleman RL: Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Prac Oncol 5: 194-204, 2008. (Pubitemid 351493679)
11. Chen H, Ye D, Xie X, Chen B and Lu W: VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma. Gynecol Oncol 94: 630-635, 2004. (Pubitemid 39194453)
12. Boocock CA, Charnock-Jones DS, Sharkey AM, et al: Expression of vascular endothelial growth factor and its receptors fit and KDR in ovarian carcinoma. J Natl Cancer Inst 87: 506-516, 1995.
13. Sher I, Adham SA, Petrik J and Coomber BL: Autocrine VEGF-A/KDR loop protects epithelial ovarian carcinoma cells from anoikis. Int J Cancer 124: 553-561, 2009.
14. Wang FQ, Barfield E, Dutta S, Pua T and Fishman DA: VEGFR-2 silencing by small interference RNA (siRNA) suppresses LPA-induced epithelial ovarian cancer (EOC) invasion. Gynecol Oncol 115: 414-423, 2009.
15. Alper O, Bergmann-Leitner ES, Bennett TA, Hacker NF, Stromberg K and Stetler-Stevenson WG: Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. J Natl Cancer Inst 93: 1375-1384, 2001. (Pubitemid 32936814)
16. Seo DW, Li H, Qu CK, et al: Shp-1 mediates the antiproliferative activity of tissue inhibitor of metalloproteinase-2 in human microvascular endothelial cells. J Biol Chem 281: 3711-3721, 2006. (Pubitemid 43845989)
17. Seo DW, Kim SH, Eom SH, et al: TIMP-2 disrupts FGF-2-induced downstream signaling pathways. Microvasc Res 76: 145-151, 2008.
18. Fukumura D, Kashiwagi S and Jain RK: The role of nitric oxide in tumour progression. Nat Rev Cancer 6: 521-534, 2006. (Pubitemid 43980541)
19. Schlessinger J: Cell signaling by receptor tyrosine kinases. Cell 103: 211-225, 2000.
20. Nicholson KM and Anderson NG: The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 14: 381-395, 2002. (Pubitemid 34214843)
21. Schmelzle T and Hall MN: TOR, a central controller of cell growth. Cell 103: 253-262, 2000.
22. Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and its receptors. Nat Med 9: 669-676, 2003. (Pubitemid 36749215)
23. Fujimoto J, Sakaguchi H, Aoki I, Khatun S and Tamaya T: Clinical implications of expression of vascular endothelial growth factor in metastatic lesions of ovarian cancers. Br J Cancer 85: 313-316, 2001. (Pubitemid 32747694)
24. Mesiano S, Ferrara N and Jaffe RB: Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 153: 1249-1256, 1998. (Pubitemid 28465848)
25. Burton BK, Kar S and Kirkpatrick P: Sapropterin. Nat Rev Drug Discov 7: 199-200, 2008. (Pubitemid 351321231)
26. Blau N, van Spronsen FJ and Levy HL: Phenylketonuria. Lancet 376: 1417-1427, 2010.
27. Stevens EV, Carpenter AW, Shin JH, Liu J, Der CJ and Schoenfisch MH: Nitric oxide-releasing silica nanoparticle inhibition of ovarian cancer cell growth. Mol Pharm 7: 775-785, 2010.
28. Garban HJ and Bonavida B: Nitric oxide sensitizes ovarian tumor cells to Fas-induced apoptosis. Gynecol Oncol 73: 257-264, 1999. (Pubitemid 29215741)
29. Farias-Eisner R, Sherman MP, Aeberhard E and Chaudhuri G: Nitric oxide is an important mediator for tumoricidal activity in vivo. Proc Natl Acad Sci USA 91: 9407-9411, 1994. (Pubitemid 24297923)
30. Hefler LA, Ludwig E, Lampe D, et al: Polymorphisms of the endothelial nitric oxide synthase gene in ovarian cancer. Gynecol Oncol 86: 134-137, 2002. (Pubitemid 34953494)
31. Raspollini MR, Amunni G, Villanucci A, et al: Expression of inducible nitric oxide synthase and cyclooxygenase-2 in ovarian cancer: correlation with clinical outcome. Gynecol Oncol 92: 806-812, 2004. (Pubitemid 38251381)
32. Olson TA, Mohanraj D, Carson LF and Ramakrishnan S: Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res 54: 276-280, 1994. (Pubitemid 24042123)
33. Yamamoto S, Konishi I, Mandai M, et al: Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer 76: 1221-1227, 1997. (Pubitemid 27448021)
34. Hartenbach EM, Olson TA, Goswitz JJ, et al: Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. Cancer Lett 121: 169-175, 1997. (Pubitemid 28008916)
35. So J, Wang FQ, Navari J, Schreher J and Fishman DA: LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2). Gynecol Oncol 97: 870-878, 2005. (Pubitemid 40824659)